Precigen PE Ratio 2012-2021 | PGEN

Current and historical p/e ratio for Precigen (PGEN) from 2012 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Precigen PE ratio as of January 19, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Precigen PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-01-20 2.96 0.00
2021-09-30 4.99 $-0.57 0.00
2021-06-30 6.52 $-0.60 0.00
2021-03-31 6.89 $-0.76 0.00
2020-12-31 10.20 $-1.02 0.00
2020-09-30 3.50 $-1.88 0.00
2020-06-30 4.99 $-2.05 0.00
2020-03-31 3.40 $-2.04 0.00
2019-12-31 5.48 $-2.09 0.00
2019-09-30 5.72 $-3.59 0.00
2019-06-30 7.66 $-3.68 0.00
2019-03-31 5.26 $-3.94 0.00
2018-12-31 6.54 $-3.87 0.00
2018-09-30 17.22 $-1.51 0.00
2018-06-30 13.94 $-1.40 0.00
2018-03-31 15.33 $-1.05 0.00
2017-12-31 11.52 $-0.98 0.00
2017-09-30 19.01 $-1.12 0.00
2017-06-30 24.09 $-1.03 0.00
2017-03-31 19.82 $-1.29 0.00
2016-12-31 24.04 $-1.58 0.00
2016-09-30 27.73 $-1.49 0.00
2016-06-30 24.35 $-1.59 0.00
2016-03-31 33.53 $-1.54 0.00
2015-12-31 29.83 $-0.74 0.00
2015-09-30 31.47 $-0.28 0.00
2015-06-30 48.29 $-0.47 0.00
2015-03-31 44.89 $-0.63 0.00
2014-12-31 27.24 $-0.84 0.00
2014-09-30 18.38 $-1.15 0.00
2014-06-30 24.87 $-0.47 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.620B $0.103B
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.655B 9.08
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.351B 19.22
Biohaven Pharmaceutical Holding (BHVN) United States $7.535B 0.00
Emergent Biosolutions (EBS) United States $2.453B 8.82
Arcus Biosciences (RCUS) United States $2.353B 0.00
Myovant Sciences (MYOV) United Kingdom $1.344B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.156B 0.00
Zymeworks (ZYME) Canada $0.627B 0.00
Ambrx Biopharma (AMAM) United States $0.207B 0.00
SQZ Biotechnologies (SQZ) United States $0.207B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81